The ASX closed the week on a positive note, gaining 0.50% to close 1.4% higher than last week.

The ASX 200 closed at 7,523 while the ASX Emerging Companies Index rose 2.09% to close at 2,431.

Most sectors closed positive with materials the best sector gaining 1.17% while tech was the only major laggard, retreating 0.76%.

 

TODAY’S BIGGEST WINNERS

Scroll or swipe to reveal table. Click headings to sort.

ASX investors woke this morning to news that the spot uranium price went above US$37/lb for the first time in six years.

Literally all of the ASX’s uranium stocks gained with the best being  92Energy (ASX:92E) which gained over 60%.

Ballymore Resources (ASX:BMR), a Queensland focused gold and base metals exploration company, rose 75% on its ASX debut.

 

TODAY’S BIGGEST LOSERS

Scroll or swipe to reveal table. Click headings to sort.

CZR Resources (ASX: CZR) announced 4 directors quit after the board was unable to reach a consensus on development opportunities for the Robe Mesa Iron ore project.

Cellnet (ASX:CLT) told shareholders Optus would not be renewing a mobile accessories supply agreement between the pair.

 

ANNOUNCEMENTS YOU MAY HAVE MISSED

Nearly a month since Glencore bought 9.99% of Chile-focused gold-copper explorer Hot Chili (ASX:HCH), Glencore appointed Mark Jamieson to the board. Jamieson is currently general manager of resource engineering for Glencore’s global copper asset group.

DC Two (ASX:DC2) announced its data centre in Western Melbourne advanced into the next stage of commercialisation with its project partner buying an individual unit for $482,396. The company said while selling individual units was not currently a corporate priority, the company would look into the commercial viability of this potential revenue stream.

BCAL Diagnostics (ASX:BDX) announced it had begun collecting samples for the first stage of its Australian clinical program. The company will use the samples to evaluate the potential of its blood-based test to detect breast cancer.

Neuren Pharmaceuticals’ (ASX:NEU) NNZ-2591 drug was granted Orphan Drug designation by the FDA for the treatment of Prader-Willi Syndrome. Orphan Drug designation gives the company – among other benefits – 7 years of marketing exclusivity as well as a waiver of the prescription drug user fee for a marketing application.

Engineering firm CIMIC (ASX:CIM) announced its subsidiary UGL was granted two contract extensions for planning, maintenance and shutdown services for the oil and gas sector in WA. CIMIC says these deals would generate revenues of approximately $160 million.

 

TRADING HALTS

Monday

Diatreme Resources (ASX:DRX) – capital raising
Houston We Have (ASX:HWH) – material contract
Kaiser Reef (ASX:KAU) – capital raising
Pan Asia Metals (ASX:PAM) – capital raising
Kleos Space (ASX:KSS) – capital raising

Tuesday

TNT Mines (ASX:TIN) – project acquisition
Aruma Resources (ASX:AAJ) – capital raising
Sacgasco (ASX:SGC) – acquisition
DUG Technology (ASX:DUG) – capital raising
Jadar Resources (ASX:JDR) – project acquisitions